FindTrial
Sign In

Effect of domperidone containing antiemetic regimen on the electrical activity of heart in patients with malignancy

Effect of Domperidone, 5-HT3 Antagonist and Olanzapine Containing Antiemetic Regimen on QT interval in Patients with Malignancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/09/015676
Enrollment
40
Registered
2018-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms Health Condition 2: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Dr Ashwin Kamath
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Will be receiving domperidone, 5-HT3 antagonist and olanzapine containing antiemetic regimen 2. ECOG status 3. Willing to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Baseline QTc interval > 450 milliseconds 2. History of cardiac arrhythmias 3. A history of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) 4. The use of concomitant medications that prolong the QT/QTc (other than the study drugs) 5. If the investigator is of the opinion that the patient will be unable to complete the study due to any reasons

Design outcomes

Primary

MeasureTime frame
Change from baseline in QT intervalTimepoint: Day 0, 1, 2, 3—

Secondary

MeasureTime frame
Change from baseline in heart rateTimepoint: Day 0, 1, 2, 3—

Countries

India

Contacts

Public ContactDr Ashwin Kamath

Kasturba Medical College, Mangaluru

ashwin.kamath@manipal.edu

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026